Tag Archives: LXRP

Top Blue Chip Stocks To Own Right Now

This is part of a series of stories that comprise TheStreet’s Blue Chip Studio, which will illuminate issues related to corporate board performance, activism, dealmakers and personalities revealed by analysis of data generated by BoardEx, a business unit of TheStreet.

BlackRock (BLK), the world’s largest asset manager, said it will be putting pressure on companies to address boardroom diversity as part of a series of initiatives for 2017-2018 that the company’s 30-member Investment Stewardship team will discuss with portfolio companies.

The New York-based firm, with $5.1 trillion under management, said board composition, effectiveness, and accountability remain a top priority, and that it plans to engage companies in a constructive manner.

“More specifically, over the coming year, we will engage companies to better understand their progress on improving gender balance in the boardroom,” the firm said on its website on Monday. “Diverse boards, including but not limited to diversity of expertise, experience, age, race and gender, make better decisions.”

Top Blue Chip Stocks To Own Right Now: Lexaria Bioscience (LXRP)

Advisors’ Opinion:

  • [By Matthew Briar]

    What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.

    Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.

    Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.

    Pterostilbene (found in blueberries, by the way) is o

  • [By Matthew Briar]

    Granted, it’s not always a fully-appreciated distinction. Even though the federal government accurately recognizes that hemp and marijuana are only variants of the same species, Cannabis sativa, the DEAdoesn’t necessarily enforce its drug laws as such. For legitimate medical purposes, the government is perfectly willing to leave the matter alone.

    The good news is, governments – federal as well as state – are finally starting to figure out the distinct differences between marijuana and hemp, and that bodes well for a young and hungry startup called Lexaria Bioscience Corp (OTCMKTS:LXRP).

  • [By Matthew Briar]

    Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).

    Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.

    It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp

  • [By Bryan Murphy]

    When you’ve come up with a technology that increases the digestion of minerals, vitamins, compounds, nutrients, and even medicine, the first thing you want to do is protect that idea so nobody else can commercialize it except you. Well, Lexaria Bioscience Corp (OTCMKTS:LXRP) has figured out how to do the former, and it’s been doing the latter… in spades. First it started by building a wall around its platform in the United States, but as of today’s press release is building a wall internationally as well.

    It’s an exciting prospect to be sure. In simplest terms, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.

    It’s largely unrecognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes the game, so to speak. How? A proprietary process that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.

    The science: Lexaria Bioscience has defined a way to combine cannabinoids with lipids — or fatty acids — at the molecular level. It matters, because the human endocannabinoid system is itself lipid based, making this format the easiest and most effective means of introducing the medicinal and health benefits of hemp and hemp oil.

    And the results have been impressive in two different studies

  • [By Jim Robertson]

    In October, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP) was issuedU.S. Patent No. 9,474,725 Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof and now the company is seeking to expand this patent internationally. This patent protects Lexaria Bioscience Corps intellectual property related to infusion of cannabinoid compounds in edible products and includes a set of claims that describe the Companys method of combining a fatty acid compound with any non-psychoactive cannabinoid for improved bioavailability and taste performance in both food and beverage formats.

  • [By Bryan Murphy]

    Though they’re not the same thing, anything that’s good for marijuana is good for hemp. That’s why when eight out of nine states that had marijuana on the ballot two Tuesday’s ago approved those measures, things got a lot more compelling for owner of Lexaria Bioscience Corp (OTCMKTS:LXRP).

    What’s the difference? Hemp a strains of Cannabis sativa that have been bred specifically for fiber used for clothing, construction, oils and topical ointments, nutritional benefits and a wide array of other purposes that don’t involve getting “high.” Marijuana is a slang term used to describe strains of Cannabis sativa that are bred for the potent resinous glands, or trichomes, that grow on the flowers and some leaves… the strain packed with tetrahydrocannabinol (or THC).

    They would be easy to confuse, and commonly are. The potential for confusion, in fact, is the chief reason government agencies have been hesitant to support one and ban the other. With marijuana now legalized for use for one reason or another in more than half the United States though, knowledge and understanding of the difference will soon follow.

    Great, but what’s that got to do with Lexaria Bioscience is on the leading edge of the movement of heightened understanding of what hemp is, and what it does.

    The medical benefits of the non-psychoactive form of Cannabis sativa are impressive to say the least. Among other benefits, hempseed oil has also shown a positive effect on dermatological diseases and lipid metabolism (the process by which fatty acids are broken down in the body). Hempseed also has high levels of vitamins A, C and E and ?-carotene, and it is rich in minerals like phosphorus, potassium, magnesium, sulfur and calcium. As a food, hempseed oil is nutritious – it contains an excellent balance of polyunsaturated fatty acids – and it reportedly tastes good, too.

    Problem: Hemp isn’t effectively absorbed into the body, and as such, it’s difficult to make effec

Top Blue Chip Stocks To Own Right Now: Dow Treasuries(DV)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart of Apollo Education Group along with peersITT Educational Services, Inc (NYSE: ESI) and DeVry Education Group Inc (NYSE: DV) reflect the headwinds from the Obama administration:

Top Blue Chip Stocks To Own Right Now: Check Point Software Technologies Ltd.(CHKP)

Advisors’ Opinion:

  • [By Jayson Derrick]

    It is unclear which company or companies will benefit from this executive order. But that isn’t stopping investors from placing their bets as most cybersecurity stocks were trading higher during Friday’s trading session; at the same time, the Dow Jones Industrial Average and S&P 500 index were trading in the red.

    Shares of Barracuda Networks Inc (NYSE: CUDA) were trading higher by 2.98 percent at $21.77. Shares of Check Point Software Technologies Ltd. (NASDAQ: CHKP) were trading higher by 1.21 percent at $107.00. Shares of FireEye Inc (NASDAQ: FEYE) were trading higher by 0.70 percent at $14.55. Shares of Palo Alto Networks Inc (NYSE: PANW) were trading higher by 0.62 percent at $115.86.

    Related Links:

  • [By WWW.THESTREET.COM]

    Turning Around Cybersecurity Through Activism
    As competition climbs and spending slows, security has attracted activists. (FEYE) (IMPV) (FTNT) (CHKP) Full story

  • [By Harsh Chauhan]

    But is it a good idea to buy FireEye based on this one incident, despite its huge losses, or should investors look at Check Point Software Technologies(NASDAQ:CHKP), given its focus on growing its bottom line? Let’s find out.

Top Blue Chip Stocks To Own Right Now: Embraer-Empresa Brasileira de Aeronautica(ERJ)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Friday, industrials shares fell by 0.12 percent. Meanwhile, top losers in the sector included Stericycle Inc (NASDAQ: SRCL), down 17 percent, and Embraer SA (ADR) (NYSE: ERJ), down 13 percent.

  • [By Paul Ausick]

    Boeing also confirmed on Thursday that it has discussed a “possible combination” with Brazil’s Embraer S.A. (NYSE: ERJ), a response to the deal Bombardier struck with Airbus in which the European company took control of Bombardier’s C Series program. A deal between Boeing and Embraer is no sure thing, mainly because the Brazilian government holds a controlling interest in Embraer.

Top Blue Chip Stocks To Own Right Now: SPDR S&P Bank ETF (KBE)

Advisors’ Opinion:

  • [By ]

    Shares of banks have underperformed this year on a narrow net interest margin, the difference between long-term and short-term rates, and continued regulatory costs from post-crisis legislation. The SPDR S&P Bank ETF (NYSE: KBE) has returned just 3.3% this year versus a 15% increase in the broader S&P 500 index.

  • [By Ben Levisohn]

    The market clearly likes the rate hike today. The S&P 500 has gained 1% to2,388.03 at 3:01 p.m. today. The Financial Select Sector SPDR ETF (XLF) has is little changed at $24.78, while the SPDR S&P Bank ETF (KBE) has dropped 0.7% to $44.59.

  • [By Ben Levisohn]

    Heck, it might just be easier to buy the lot, especially if you think earnings will be awesome. There’s an ETF for that you know (the SPDR S&P Bank ETF (KBE))?

Top Blue Chip Stocks To Own Right Now: UNIVERSAL INSURANCE HOLDINGS INC(UVE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Small cap Florida insurance stock Universal Insurance Holdings (NYSE: UVE) has taken a hit with shares downalmost 17%over the past week on predictions that Hurricane Irma would hit Florida albeit sharesrose 8.51%on Friday when it became clear that it would not be as catastrophic as feared:

stock market trading hours

The debt crisis in Greece has been going on for nearly a decade, and now Greece is on the verge of its fourth bailout in seven years.

Here’s a complete breakdown and timeline of the debt crisis in Greece…

Timeline of the Debt Crisis in Greece: 2007-2008

Greece was hit especially hard during the global economic recession of 2007 and 2008. Before the crisis, country officials had been understating the deficit for years. Greece was burning through cash faster than anyone knew.

Don’t Miss: Trump’s Secret Weapon Set to Foil China’s Master Plan

When the recession hit, Greece couldn’t keep hiding its deficit problem because it could no longer pay its bills.

2009: Greece’s Debt Begins to SoarOct. 20: Budget deficit of Greece expected to reach approximately 12.5% of GDP. The deficit exceeds the 3% of GDP set for Eurozone member states by the Stability and Growth Pact.December: All three credit rating agencies downgrade Greece’s credit rating.

Once Greece announced it was understating its deficit and announced the true deficit in October 2009, the country was unable to borrow money on the open market. The announcement called into question the financial stability of Greece.

stock market trading hours: Thor Industries Inc.(THO)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In his second “Executive Decision” segment, Cramer spoke with Bob Martin, president and CEO of Thor Industries (THO) , a stock that was crushed today, down 9.8%, on a penny-a-share earnings beat with tempered guidance.

  • [By Peter Graham]

    A long term performance chart shows shares of Winnebago Industries and small cap peer Thor Industries, Inc (NYSE: THO) giving a similar performance with shares taking off last year before stumbling this year while Drew Industries, Inc (NYSE: DW) has mostly underperformed:

  • [By Peter Graham]

    A long term performance chart shows shares of Winnebago Industriesalong withmid cap peers Thor Industries, Inc (NYSE: THO) and LCI Industries (NYSE: LCII) all giving a very similar performance and largely taking off starting in 2016:

stock market trading hours: Abbott Laboratories(ABT)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Abbott Laboratories (ABT) , Dycom Industries (DY) and Howard Hughes (HHC) .

    Cramer was bearish on Headwaters (HW) , EnergySolutions (ES) , Western Refining (WNR) and Horizon Pharmaceuticals (HZNP) .

  • [By Sean Williams]

    Finally, and as the icing on the cake, Wall Street uncovered via a Securities and Exchange Commission filing that Abbott Laboratories (NYSE:ABT) sold 44 million shares of Mylan stock at $41.60, reducing its remaining position in the company to 25.75 million shares, or about 4.8% of its outstanding shares. Considering all the issues Mylan has had recently, the fact that Abbott substantially pared its large holding in the company is a bit worrisome.

  • [By Matt Hogan]

    AbbVie has distributed a significant amount of its earnings in the form of dividends (~60 percent) since the company spun off from Abbott Laboratories (NYSE: ABT) in 2013. The company appears to be trading at a 10 percent discount to fair value when applying similar assumptions in the 5-year dividend discount model as shown below.

stock market trading hours: Sigma Designs, Inc.(SIGM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Sigma Designs Inc (NASDAQ: SIGM) shares dropped 30 percent to $5.43. Sigma Designs reported fiscal third-quarter net income of $221,000 on revenue of $62.7 million.

  • [By Paul Ausick]

    Sigma Designs Inc. (NASDAQ: SIGM) dropped about 34% on Wednesday to post a new 52-week low of $5.20 against a 52-week high of $8.60 and a Tuesday close of $7.75. Volume of about 6.2 million was about 25 times the daily average of around 280,000. The company reported so-so earnings on Tuesday and the stock was downgraded and price targets lowered by several analysts.

  • [By Lisa Levin]

    Gainers

    Pyxis Tankers Inc. (NYSE: PXS) rose 47.48 percent to $$5.56, after the company announced it has entered into a definitive securities purchase agreement with a group of investors, which will result in gross proceeds of $4.8 million.
    Sigma Designs Inc (NASDAQ: SIGM) rose 22.77 percent to $6.88. Silicon Laboratories (NASDAQ: SLAB) announced plans to buy Sigma Designs for $7.05 per share in cash.
    Steadymed Ltd (NASDAQ: STDY) rose 19.35 percent to $3.70, after the company reported that no clinical trials were required for Trevyent and that the FDA had agreed to the pathway for the drug candidate's NDA resubmission.
    Iteris, Inc. (NASDAQ: ITI) rose 15.73 percent to $7.06. Earlier in the week, Zacks Investment Research had upgraded the company from "Sell" to "Hold".
    Science Applications International Corp (NYSE: SAIC) rose 13.71 percent to $85.77 as the company reported better-than-expected earnings for its third quarter.
    Technical Communications Corporation (NASDAQ: TCCO) rose 12.41 percent to $6.07, after having risen sharply in pre-marketing trading.
    Radius Health, Inc. (NASDAQ: RDUS) rose 12.41 percent to $30.81 after the company provided an update on data from the Phase 1 005 clinical study of elacestrant in patients with estrogen receptor positive breast cancer during the 2017 San Antonio Breast Cancer Symposium.
    ForeScout Technologies, Inc. (NASDAQ: FSCT) rose 12.32 percent to $25.80 after the company reported its third quarter financial results.
    Prana Biotechnology Limited (NASDAQ: PRAN) rose 11.36 percent to $3.43, as the company announced a research collaboration with Takeda Pharmaceuticals to study the ability of movement disorders compound, PBT434 to slow or prevent neurodegeneration of the gastrointestinal system.
    Catalyst Biosciences, Inc. (NASDAQ: CBIO) rose 10.49 percent to $7.90 as the company announced the appointment of Arwa Shurrab and Jamie Ellen Siegel in its clinical hemophilia

stock market trading hours: Daktronics, Inc.(DAKT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is projected to report its quarterly earnings at $0.08 per share on revenue of $156.17 million.

    Guidewire Software Inc (NYSE: GWRE) is estimated to post its quarterly earnings at $0.06 per share on revenue of $92.43 million.

  • [By Monica Gerson]

    Daktronics, Inc. (NASDAQ: DAKT) is estimated to report its quarterly earnings at $0.08 per share on revenue of $156.17 million. Daktronics shares slipped 0.13 percent to close at $7.97 on Tuesday.

stock market trading hours: TheStreet, Inc.(TST)

Advisors’ Opinion:

  • [By Steven Goldberg]

    Launched in August 2001, Action Alerts PLUS Portfolio has been a centerpiece of the financial advice offered by TheStreet.com. The website belongs to TheStreet, Inc. (TST), a publicly traded company that Cramer co-founded in 1996. PLUS Portfolio subscribers, who pay $15 a month, always get the recommendations before Cramer buys them for the portfolio, the Wharton paper reports. Likewise, subscribers get Cramers picks before he airs them on Mad Money.

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

stock market trading hours: Lexaria Bioscience (LXRP)

Advisors’ Opinion:

  • [By James E. Brumley]

    Are hemp and marijuana one and the same? It depends who you ask. The federal government accurately recognizes that hemp and marijuana are variants of the same species, Cannabis sativa. Yet, poodles and German shepherds are also from the same species, and the two couldn’t be any more different types of dogs. The same goes for marijuana and hemp. The difference between hemp and marijuana is primarily the amount of tetrahydrocannabinol (or THC), which is the primary psychoactive chemical in marijuana. Hemp contains less than 0.5% THC, while marijuana consists of anywhere from 6 % to 20% (and sometimes more) THC.

    The good news is, governments – federal and state – are finally starting to wise up to the distinct differences between marijuana and hemp, and that bodes well for a young startup called Lexaria Bioscience Corp (OTCMKTS:LXRP).

    Lexaria Bioscience Corp. is “a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.”

    In other words, it solves a problem within the budding (no pun intended) world of cannabis and medical — or even recreational — marijuana. It increases the amount of absorption of a substance ingested.

    The science has applications in everything from vitamins to supplements to painkillers, but LXRP is starting with the hemp oil for good reason.

    Hemp seeds (which are technically a nut and are als

  • [By Bryan Murphy]

    At first glance, it looks like it could be trouble for Lexaria Bioscience Corp (OTCMKTS:LXRP). That is, on Wednesday, the nation’s Drug Enforcement Agency brought clarity to a rule that had been up in the air since 2011. That is, in short, the DEA’s position on all cannabis extracts, including CBD oil, is that they are all federally illegal Schedule I substances.

    From a legal and logical standpoint based just on the DEA’s language published in the Federal Register yesterday, that puts Lexaria Bioscience in jeopardy. Lexaria has developed a way to improve the body’s absorption of hemp oil — which is deliberately high in cannabidiol/CBD — which was perfectly legal and legitimate since THC percentage in hemp (0.3%or less) are technically legal. Now the federal government’s drug-enforcement arm says that’s not the case. The newly-clarified law defines the illegal substance as “extracts that have been derived from any plant of the genus Cannabis and which contain cannabinols and cannabidiols.” Hemp, even though it’s not marijuana, is of the Cannabis genus.

    Bad news for LXRP owners? Not quite, for a handful of reasons.

    The decision (which bypassed legislature and overstepped the DEA’s authority, by the way – more on that in a second) is evidence of a long-standing problem the government agency has had in dealing with hemp and cannabis. In simplest terms, the DEA has operated and acted as if it has no real understanding of the difference between hemp and marijuana. They are of the same genus, but not of the same species. Moreover, while the former predominantly contains cannabidiol, the latter is sought out for its high tetrahydrocannabinol (or THC) for the purpose of creating a “high.”

    Problem (for the DEA): The U.S. judicial system has already ruled that the DEA doesn’t have the authority to make such rules.

    Attorney Robert Hoban explained yesterday evening at industry website newcannabisventures.com:

  • [By Jim Robertson]

    Small cap Lexaria Bioscience Corp (OTCQB: LXRP)is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies.This technology enables higher bioavailability rates for CBD, THC, NSAIDs, Nicotine and other molecules than is possible without lipophilic enhancement technology allowing for lower overall dosing requirements and/or higher effectiveness in active molecule delivery.The Companyhopes to reduce other common, but less healthy ingestion methods such as smoking as it embraces the benefits of public health.

investment adviser

Lululemon Athletica (LULU) is scheduled to release its financial results on March 29 after the market close. And while half of the 36 analysts who Lululemon rate it a Buy or Outperform, that still means another half, well, don’t.

Kevork Djansezian/Getty Images

Count Macquarie’s Laurent Vasilescu and team among the latter. In a note today, they offered 10 reasons to be cautious about Lululemon, which they rate Underperform. Here are my excerpts:

Same-store Sales: “We are concerned that store comps are in the low single digits, especially since the store fleet is very young,” Vasilescu warns. Margin Disclosure: “The level of disclosure around the gross margin continues to decrease,” Vasilescu claims. Margin Sapping Businesses: “Mens and ivivva are both growth drivers yet they are
margin dilutive,” Vasilescu explains. Too many stores in the U.S.: “Prior management outlined many times the TAM of 300-350 stores in North America,”Vasilescu writes. “Lulu is reaching saturation.” U.S. Store Profitability: It’s much lower than in Canada, claims Vasilescu. Marketing: Not enough of it, especially compared to Nike (NKE), Adidas (ADDYY), and Under Armour (UAA), Vasilescu says. Not a tech company: On its third-quarter conference call, Lululemon said it was a quasi-tech company. It’s not, says Vasilescu. Competition: Denim. Beyonce. Amazon.com (AMZN). Ouch. High costs: “When comps turn negative we think this will pressure earnings, as we estimate high fixed SG&A costs,” write Vasilescu. Inventories: “Days in inventory remain elevated at 112 vs historical 3Q rate of 90,” warns Vasilescu.

Shares of Lululemon Athletica have gained 0.6% to $64.06 at 2:32 p.m. today, while Nike has fallen 0.9% to $55.86, Adidas has dipped 0.1% to $96.27, Under Armour has risen 0.9% to $19.83, and Amazon.com has ticked up 0.1% to $846.38.

investment adviser: Popeyes Louisiana Kitchen, Inc.(PLKI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Popeyes Louisiana Kitchen Inc (NASDAQ: PLKI) is estimated to post its quarterly earnings at $0.64 per share on revenue of $85.31 million.

    SpartanNash Co (NASDAQ: SPTN) is expected to post its quarterly earnings at $0.49 per share on revenue of $2.28 billion.

  • [By Ashley Moore]

    Popeyes Louisiana Kitchen Inc. (Nasdaq: PLKI) stock is up 19% today (Tuesday) after Burger King’s parent company, Restaurant Brands International Inc. (NYSE: QSR), announced it will buy the fast-food chicken company.

  • [By Daniel Miller]

    While chicken and burgers might not sound like a match made in heaven for dinner, it could be tasty for investors inRestaurant Brands International (NYSE:QSR). The parent company of Burger King agreed to purchase Popeyes Louisiana Kitchen Inc. (NASDAQ:PLKI).

investment adviser: Advance Auto Parts Inc(AAP)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    So here’s a disruptive move. Consider buying auto parts retailer Advance Auto Parts (AAP) , the weakest of the big three in the sector, which has 5,000-plus locations in the U.S. The other two players are O’Reilly Automotive, Inc. (ORLY) , the fastest-growing of the three, and AutoZone, Inc. (AZO) .

  • [By Spencer Israel]

     

    Riot Blockchain Inc (NASDAQ: RIOT) – The Jan. 2015 high of $15.72 is the only resistance it has.
    General Electric Company (NYSE: GE) -The low of the move is a double bottom at $17.46 and  $17.50. That’s support.
    Overstock.com Inc (NASDAQ: OSTK) – The February 2005 high was $58.24, which is the only relevant resistance up here. On weakness, keep an eye on the all-time closing high of $56.65 made on Monday.
    Advance Auto Parts, Inc. (NYSE: AAP) – Is trying to fill the gap from earnings between $82.82 and $94.75.
    Tesla Motors Inc (NASDAQ: TSLA) – It needs to clear Friday’s close of $315.05 and Monday’s high of $315.50 to find support.
    Urban Outfitters, Inc. (NASDAQ: URBN) – There was a double close at $27.90 from Friday and $28.27 from Monday, so that’s resistance.
    DSW Inc. (NYSE: DSW) -The premarket low was $18.40. There are also four daily lows at the $18.40 area from early November, and the low of the move is $17.89.
    Signet Jewelers Ltd. (NYSE: SIG) – the premarket low was $61.50, which was the low of the move. There’s daily lows at the $61 area from mid-August, and another pair of lows at $60. Below that, there’s a gap area down to $52.95.
    Lowe’s Companies, Inc. (NYSE: LOW)- The Friday low was $79.17, and a pair of lows from Wednesday and Thursday at $78.27 and $78.23.
    Campbell Soup Company (NYSE: CPB) – The buy zone is between $45-$46. The low of the move was $44.99, flanked by the $45.14 low the following day.
    Dollar Tree, Inc. (NASDAQ: DLTR) – $99.93 and a big psychological number at $100.
    Burlington Stores Inc (NYSE: BURL) – The Monday low was $104.55. The all-time high and all-time closing high are $106.55 and $106.89, respectively. 
    Exxon Mobil Corporation (NYSE: XOM) – Big triple bottom at $80.

    Watch the full show below!

  • [By ]

    3. Advance Auto Parts (NYSE: AAP)
    A leader in the consumer auto parts space, Advance boasts over 5,200 stores, 100 Worldpac branches, and serves more than 1,300 independently owned CARQUEST branded shops.

  • [By Ben Levisohn]

    Advance Auto Parts (AAP) surged to the top of the S&P 500 today after releasing better-than-expected third-quarter earnings.

    Getty Images

    Shares of Advance Auto Parts gained 15% to $164.33, while the S&P 500 rose 0.8% to 2,180.39.

    Credit Suisse analyst Seth Sigman and team explain why shares of Advance Auto Parts are soaring:

    Advance Auto Parts’ Q3 and strategic update was one of the better scenarios for this stock with better than expected comps, positive commentary on Q4, a roughly in line 2017 outlook, and a new sense of direction on how this new management team will narrow the margin gap with peers. Management guided to a 500 bps long-term margin improvement, which wasnt a surprise to investors, and other specifics were still limited. However, timed with Q3/4′s improvement, this should help instill some early confidence in this team. We are adjusting our 2016 and 2017 EPS modestly, to $7.30 (from $7.23) and to $7.65 (from $7.60) respectively.

    Advance Auto Parts market capitalization rose to $12.1 billion today from $10.7 billion yesterday.

investment adviser: Alphabet Inc.(GOOGL)

Advisors’ Opinion:

  • [By Douglas A. McIntyre]

    Alphabet Inc.’s (NASDAQ: GOOGL) Google was one of the first companies to field early experiments in self-driving cars. By late last year, Google’s vehicles had covered over 2 million miles on public roads. Google has spun out its driverless car operation into a company called Waymo. Its management commented:

  • [By Elizabeth Balboa]

    The marketing and sales software platform is also facing competition from the likes of Alphabet Inc (NASDAQ: GOOGL) and Facebook Inc (NASDAQ: FB).

    “At best, HubSpot is worth SaaS [software as a service] comps,” Left wrote. “We give it the benefit of the doubt and give it take-out valuations… Hubspot is more in line with a content marketing company whose takeout valuations are 2x revenue.”

  • [By Daniel Sparks]

    Alphabet (NASDAQ:GOOG) (NASDAQ:GOOGL) has put its first-quarter earnings release date on the calendar. The internet search giant will report results for its most recently ended quarter on Thursday, April 27. After missing estimates for earnings per share in its most recent quarter, investors will be watching the company’s profitability closely.

  • [By WWW.THESTREET.COM]

    Are you sensing a little resistance? Cramer and the AAP team look at Apple (AAPL) , Facebook (FB) , Alphabet (GOOGL) , and Schlumberger (SLB) in their weekly roundup. Be ready for the week ahead and find out what they’re telling their investment club members with a free trial subscription to Action Alerts PLUS.

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Amazon.com, Inc. (NASDAQ: AMZN): Free Stock Analysis Report
     
    Netflix, Inc. (NASDAQ: NFLX): Free Stock Analysis Report
     
    Facebook, Inc. (NASDAQ: FB): Free Stock Analysis Report
     
    Alphabet Inc. (NASDAQ: GOOGL): Free Stock Analysis Report
     
    Apple Inc. (NASDAQ: AAPL): Free Stock Analysis Report
     
    SPDR-TECH SELS (ETF:XLK): ETF Research Reports
     
    NASDAQ-100 SHRS (NASDAQ: QQQ): ETF Research Reports
     
    SPDR-SP 500 TR (ETF:SPY): ETF Research Reports
     
    PWRSH-DYN SEMI (ETF:PSI): ETF Research Reports
     
    ISHARS-NA TEC-S (ETF:IGV): ETF Research Reports
     
    FIRST N-100 TEC (NASDAQ: QTEC): ETF Research Reports
     
    FT-TECH ALPHA (ETF:FXL): ETF Research Reports
     
    FT-NDQ SEMICON (FTXL): ETF Research Reports
     
    NVIDIA Corporation (NASDAQ: NVDA): Free Stock Analysis Report
     
    Macy's Inc (NYSE: M): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research
     
    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

investment adviser: Prudential Financial Inc.(PRU)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Cramer was bearish on Prudential (PRU) , Advanced Semiconductor Engineering (ASX) and ZTO Express (ZTO) .

    Read more of Cramer’s comments about the stocks in the Lightning Round.

  • [By WWW.MONEYSHOW.COM]

    Prudential Financial (PRU) is also a major provider of asset management and retirement services. It focuses is on fixed income, a major liability during the past eight years of ultra-low interest rates.

  • [By Chuck Saletta]

    Prudential Financial (NYSE:PRU) has long had the Rock of Gibraltar as its corporate symbol, representing its solid financial position. With more cash and equivalents than debt on its balance sheet, and a total cash hoard of over $49 billion, Prudential still looks set up to handle some downright awful insurable losses. That’s its “Rock of Gibraltar” strength showing through.

investment adviser: Lexaria Bioscience (LXRP)

Advisors’ Opinion:

  • [By Matthew Briar]

    Earlier this month, some light was shed on the so-called marijuana ‘zombie’ outbreak in Brooklyn (and a handful of other places) earlier this year. As it turns out, it wasn’t a zombie outbreak at all… not that anyone really suspected the undead were lurking about. The culprit was drugs, or more specifically, chemicals and compounds that serve as drugs that weren’t meant to be utilized in that manner. In the search for a stronger, more intense high, marijuana fans got far more than they bargained for, and not in good way.

    The matter inadvertently puts an up-and-coming company called Lexaria Bioscience Corp (OTCMKTS:LXRP) in the spotlight. See, Lexaria Bioscience could have sidestepped the zombie-like response of what’s now clearly been deemed a chemical-laced plant nobody would ever actually choose to smoke if they knew better. How so? Because LXRP could have provided the more intense ‘high’ being sought using its infusion science and real marijuana… not the synthetic marijuana that’s been causing unexpected results like hallucinations, extreme agitation, a rapid heartbeat and extremely high blood pressure. paranoia, anxiety, panic attacks and psychotic episodes. Those aren’t the usual responses to weed. They’re common responses to other, harsher narcotics, and are often wished avoided by recreational marijuana users.

    Say what you want about the moral hazards or dangers of legalized marijuana, but nobody can deny that it’s happening… in the United States, and abroad. In November, marijuana was on the ballot for one reason or another in nine states, and the pro-marijuana movement got the green light in eight of them. Weed is now legal, either for medicinal or recreational use, in more than half the states that make up the U.S.A.

    More relevant to the matter at hand, in step with the ongoing legalization of marijuana, users and sellers have — as they always do– pushed the limits of legality and science to come up with a better expe

  • [By James E. Brumley]

    Don’t be surprised if Lexaria Bioscience Corp (OTCMKTS:LXRP) shares seem a little peppier and even more bullish than usual for the next three months, give or take… and that’s saying something considering LXRP is 158% since early October, and up 47% since mid-December. Why’s that? The organization has hired a publicity firm to help tell its story to an even bigger audience, and that attention could attract a whole new batch of buyers for the stock.

    Granted, the Lexaria Bioscience story is a compelling one to begin with.

    If 2016 (and 2017 so far) were to be pegged with any major investment “themes,” cannabis would have to be it. Marijuana/hemp — cannabinoids, ultimately — was on the ballot for one reason or another in nine states this past November, and those pro-cannabis measures passed in eight of those votes. As such, cannabis is now legal for at least one reason in 26 states of the United States, and the movement is still gathering momentum.

    And well it should. The recreational aspect of marijuana and cannabinoids aside, hemp (a form of cannabis plant that isn’t the kind of marijuana that provides a “high”) delivers a multitude of health benefits. Specifically, users of hemp oil find the plant-based oil improves immunity, improves cardiovascular health, moderates blood sugar, treats skin conditions, treats arthritis, inhibits osteoporosis, fights some mental disorders, and in some cases has been found to be an anti-cancer agent. Lexaria Bioscience is simply enhancing these benefits of hemp oil by enhancing the amount of hemp oil a human body can absorb when ingested.

    Simply put, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. The key to the science is the fact that Lexaria Bioscience is able to combine cannabinoids with lipids — or fatty acids — at the molecular level. It matters, because the human endocannabinoid system is it

  • [By Matthew Briar]

    Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).

    Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.

    It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp

  • [By Jim Robertson]

    Small cap Lexaria Bioscience Corp (OTCQB: LXRP)is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies.This technology enables higher bioavailability rates for CBD, THC, NSAIDs, Nicotine and other molecules than is possible without lipophilic enhancement technology allowing for lower overall dosing requirements and/or higher effectiveness in active molecule delivery.The Companyhopes to reduce other common, but less healthy ingestion methods such as smoking as it embraces the benefits of public health.

  • [By Jim Robertson]

    In October, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP) was issuedU.S. Patent No. 9,474,725 Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof and now the company is seeking to expand this patent internationally. This patent protects Lexaria Bioscience Corps intellectual property related to infusion of cannabinoid compounds in edible products and includes a set of claims that describe the Companys method of combining a fatty acid compound with any non-psychoactive cannabinoid for improved bioavailability and taste performance in both food and beverage formats.

  • [By James E. Brumley]

    Are hemp and marijuana one and the same? It depends who you ask. The federal government accurately recognizes that hemp and marijuana are variants of the same species, Cannabis sativa. Yet, poodles and German shepherds are also from the same species, and the two couldn’t be any more different types of dogs. The same goes for marijuana and hemp. The difference between hemp and marijuana is primarily the amount of tetrahydrocannabinol (or THC), which is the primary psychoactive chemical in marijuana. Hemp contains less than 0.5% THC, while marijuana consists of anywhere from 6 % to 20% (and sometimes more) THC.

    The good news is, governments – federal and state – are finally starting to wise up to the distinct differences between marijuana and hemp, and that bodes well for a young startup called Lexaria Bioscience Corp (OTCMKTS:LXRP).

    Lexaria Bioscience Corp. is “a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.”

    In other words, it solves a problem within the budding (no pun intended) world of cannabis and medical — or even recreational — marijuana. It increases the amount of absorption of a substance ingested.

    The science has applications in everything from vitamins to supplements to painkillers, but LXRP is starting with the hemp oil for good reason.

    Hemp seeds (which are technically a nut and are als

Top 5 Performing Stocks To Invest In Right Now

Readers who pay close attention to our annual rankings of the top-performing mutual funds may be forgiven if they exper颅ience a sense of d茅j vu with our March 2016 issue. Yes, we did publish mutual-fund rankings in our September 2015 issue. But weve decided to move our annual winners list from September to the March issue so we can base it on returns as of December 31. (On Kiplinger.com, we continue to update the rankings of top-performing mutual funds in 11 categories with new data every month.) Its fair to say that most people focus more on returns through the end of the year than they do on figures through June 30, says ex颅ecutive editor Manny Schiffres, who supervises our investing coverage.

See Also: The Kiplinger 25 — Our Favorite No-Load Mutual Funds

What a difference half a year makes. Between the September and March issues, the winners over longer time periods remained fairly stable. But adding six months of new data and subtracting six months of old numbers shook up the one-year results. Particularly affected were sector funds. In Sept颅ember, health care funds occupied the top spot in each time period, and health care still dominates the three- and five-year returns. But there has been a shift in the one-year rankings, where youll now find technology funds, financial-services funds and even a retailing-sector fund.

Top 5 Performing Stocks To Invest In Right Now: Renesola Ltd.(SOL)

Advisors’ Opinion:

  • [By Monica Gerson]

    ReneSola Ltd. (ADR) (NYSE: SOL) is estimated to report a quarterly loss at $0.04 per share on revenue of $256.05 million.

    America’s Car-Mart, Inc. (NASDAQ: CRMT) is projected to post its quarterly earnings at $0.58 per share on revenue of $149.13 million.

  • [By Lisa Levin] Gainers
    Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
    Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
    Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
    Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
    SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
    Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
    One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
    Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
    Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
    Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
    Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
    VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
    CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
    Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
    Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
  • [By Monica Gerson]

    ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 9.76 percent to $1.35 in pre-market trading. ReneSola reported Q1 earnings of $0.06 per share on revenue of $260.7 million.

  • [By Monica Gerson]

    Wall Street expects ReneSola Ltd. (ADR) (NYSE: SOL) to report a quarterly loss at $0.04 per share on revenue of $256.05 million. ReneSola shares gained 2.50 percent to close at $1.23 on Friday.

Top 5 Performing Stocks To Invest In Right Now: Gold Standard Ventures Corporation(GSV)

Advisors’ Opinion:

  • [By Sara Cornell]

    The management team member who garners the most attention right now is Dave Mathewson, VP, Head of Exploration. Dave is a geologist with more than 35 years’ experience in the gold exploration space, and specifically, in Nevada. He is credited with a number of notable discoveries for Newmont Mining Corp (NYSE: NEM), and later went on to Gold Standard Ventures Corp (NYSE: GSV) helping take that company from a start-up to a now $481 million market cap.

Top 5 Performing Stocks To Invest In Right Now: Apple Hospitality REIT, Inc.(APLE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Here is the list of stocks going ex-dividend on Monday.

    AptarGroup, Inc. (NYSE: ATR) – $0.3200 dividend, 1.6780 percent yield. AptarGroup reported weaker-than-expected Q3 results on Thursday.
    Fidelity Southern Corporation (NASDAQ: LION) – $0.1200 dividend, 2.6359 percent yield. The company, based in Atlanta, Georgia, provides financial products and services for customers.
    Apple Hospitality REIT Inc (NYSE: APLE) – $0.1000 dividend, 6.5826 percent yield. Apple Hospitality REIT, based in Richmond, Virginia, operates as a subsidiary of Apple REIT Companies.
    Targa Resources Corp (NYSE: TRGP) – $0.9100 dividend, 7.7299 percent yield. The Houston, Texas-based company provides midstream natura

Top 5 Performing Stocks To Invest In Right Now: Lexaria Bioscience (LXRP)

Advisors’ Opinion:

  • [By Jim Robertson]

    Last week, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP)announced a deal with Hempco Food and Fiber (OTCMKTS: HMPPF; TSXV: HEMP) that will take hemp foods to the next level. First of all, hemp is a variety of the Cannabis sativa plant species that is grown for the industrial uses of its derived products as the plant material can be refined into justabout anything,including paper, textiles, clothing, biodegradable plastics, paint, insulation, biofuel, food and animal feed:

  • [By Jim Robertson]

    Small cap Lexaria Bioscience Corp (OTCQB: LXRP)is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies.This technology enables higher bioavailability rates for CBD, THC, NSAIDs, Nicotine and other molecules than is possible without lipophilic enhancement technology allowing for lower overall dosing requirements and/or higher effectiveness in active molecule delivery.The Companyhopes to reduce other common, but less healthy ingestion methods such as smoking as it embraces the benefits of public health.

  • [By Matthew Briar]

    Earlier this month, some light was shed on the so-called marijuana ‘zombie’ outbreak in Brooklyn (and a handful of other places) earlier this year. As it turns out, it wasn’t a zombie outbreak at all… not that anyone really suspected the undead were lurking about. The culprit was drugs, or more specifically, chemicals and compounds that serve as drugs that weren’t meant to be utilized in that manner. In the search for a stronger, more intense high, marijuana fans got far more than they bargained for, and not in good way.

    The matter inadvertently puts an up-and-coming company called Lexaria Bioscience Corp (OTCMKTS:LXRP) in the spotlight. See, Lexaria Bioscience could have sidestepped the zombie-like response of what’s now clearly been deemed a chemical-laced plant nobody would ever actually choose to smoke if they knew better. How so? Because LXRP could have provided the more intense ‘high’ being sought using its infusion science and real marijuana… not the synthetic marijuana that’s been causing unexpected results like hallucinations, extreme agitation, a rapid heartbeat and extremely high blood pressure. paranoia, anxiety, panic attacks and psychotic episodes. Those aren’t the usual responses to weed. They’re common responses to other, harsher narcotics, and are often wished avoided by recreational marijuana users.

    Say what you want about the moral hazards or dangers of legalized marijuana, but nobody can deny that it’s happening… in the United States, and abroad. In November, marijuana was on the ballot for one reason or another in nine states, and the pro-marijuana movement got the green light in eight of them. Weed is now legal, either for medicinal or recreational use, in more than half the states that make up the U.S.A.

    More relevant to the matter at hand, in step with the ongoing legalization of marijuana, users and sellers have — as they always do– pushed the limits of legality and science to come up with a better expe

  • [By Bryan Murphy]

    In the grand scheme of things it shouldn’t be surprising, though odds are good at least a few people are surprised at how quickly it happened. That is, health supplement and healthy-foods brand name NeutriSci International Inc (CVE:NU) and the developer of a cannabis-infusion technology — a means of packing more CBD into hemp oil — called Lexaria Bioscience Corp (OTCMKTS:LXRP) have finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

    The benefits of cannabidiol, found in hemp and marijuana, are relatively well understood by the market at this point. Cannabidiol can do a human body a lot of good, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. Pterostilbene is the lesser-known of the two components of the new tablet, but no less impressive and no less beneficial. Pterostilbene is known to combat high cholesterol, high blood pressure, and oxidative stress. Combining the two is a real one-two punch for the health-conscious.

    That’s what made November’s news so exciting… NeutriSci International has an established name and marketing channel, while Lexaria Bioscience has the science that makes hemp oil far more functional. Indeed, to fully appreciate the upside for LXRP, one has to embrace Lexaria’s science and why it matters.

    The bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short,

Top 5 Performing Stocks To Invest In Right Now: Plains All American Pipeline L.P.(PAA)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    One of the largest projects is the Saddlehorn Pipeline, which Magellan is building with Plains All American Pipeline (NYSE:PAA) and Anadarko Petroleum (NYSE:APC). Both Plains All American Pipeline and Magellan own 40% of the project, which puts their total investment at $230 million apiece. They expect the project to be fully operational early next year, which is noteworthy given its robust first-year economics. Magellan estimates that it will earn eight times EBITDA on the capital deployed, or roughly $28.8 million in annual EBITDA apiece for Magellan and Plains All American Pipeline on their investment.

  • [By Dustin Parrett]

    Plains All American Pipeline (NYSE: PAA) controls 4 million barrels of crude oil and natural gas a day.

    And with higher oil prices and fewer restrictions leading to more drilling, PAA’s pipelines will be in demand in 2017.

  • [By Dustin Parrett]

    We think Plains All American Pipeline L.P. (NYSE: PAA) is one of the best oil stocks to buy this year. In fact, we see a scenario where PAA stock could jump 20% in 2017.

Top Gold Stocks To Own For 2018

Yesterday we talked about the disconnect between the daily drama from the media in Washington (doom and gloom), and what the markets have been communicating (an economic expansion is underway). Today, you might think that connection is happening—the doom and gloom scenario is finally being realized in markets. Probably not.

For perspective: As of the close yesterday, the Nasdaq was up 18% year–to–date (just five months in). Gold was in the middle of a three year range. Market interest rates (the U.S. 10–year government bond yield) was just above the middle of the range of the past four years. The dollar was not far off its strongest levels in 15 years.

Today the media has explicitly printed the headline of impeachment for Trump (actually, they’ve run those headlines a various times over the past several months). Nonetheless, stocks (the S&P 500) today are off by 1.6%.

This gets the bears very excited. I saw the story about consumer debt, surpassing 2008 levels, floating all over the Internet today. People tried to make the bubble connection—implying another debt crisis was coming.

Top Gold Stocks To Own For 2018: Lexaria Bioscience (LXRP)

Advisors’ Opinion:

  • [By Jim Robertson]

    In October, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP) was issuedU.S. Patent No. 9,474,725 Cannabinoid Infused Food and Beverage Compositions and Methods of Use Thereof and now the company is seeking to expand this patent internationally. This patent protects Lexaria Bioscience Corps intellectual property related to infusion of cannabinoid compounds in edible products and includes a set of claims that describe the Companys method of combining a fatty acid compound with any non-psychoactive cannabinoid for improved bioavailability and taste performance in both food and beverage formats.

  • [By Jim Robertson]

    Last week, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP)announced a deal with Hempco Food and Fiber (OTCMKTS: HMPPF; TSXV: HEMP) that will take hemp foods to the next level. First of all, hemp is a variety of the Cannabis sativa plant species that is grown for the industrial uses of its derived products as the plant material can be refined into justabout anything,including paper, textiles, clothing, biodegradable plastics, paint, insulation, biofuel, food and animal feed:

  • [By Jim Robertson]

    Small cap Lexaria Bioscience Corp (OTCQB: LXRP)is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies.This technology enables higher bioavailability rates for CBD, THC, NSAIDs, Nicotine and other molecules than is possible without lipophilic enhancement technology allowing for lower overall dosing requirements and/or higher effectiveness in active molecule delivery.The Companyhopes to reduce other common, but less healthy ingestion methods such as smoking as it embraces the benefits of public health.

  • [By James E. Brumley]

    Don’t be surprised if Lexaria Bioscience Corp (OTCMKTS:LXRP) shares seem a little peppier and even more bullish than usual for the next three months, give or take… and that’s saying something considering LXRP is 158% since early October, and up 47% since mid-December. Why’s that? The organization has hired a publicity firm to help tell its story to an even bigger audience, and that attention could attract a whole new batch of buyers for the stock.

    Granted, the Lexaria Bioscience story is a compelling one to begin with.

    If 2016 (and 2017 so far) were to be pegged with any major investment “themes,” cannabis would have to be it. Marijuana/hemp — cannabinoids, ultimately — was on the ballot for one reason or another in nine states this past November, and those pro-cannabis measures passed in eight of those votes. As such, cannabis is now legal for at least one reason in 26 states of the United States, and the movement is still gathering momentum.

    And well it should. The recreational aspect of marijuana and cannabinoids aside, hemp (a form of cannabis plant that isn’t the kind of marijuana that provides a “high”) delivers a multitude of health benefits. Specifically, users of hemp oil find the plant-based oil improves immunity, improves cardiovascular health, moderates blood sugar, treats skin conditions, treats arthritis, inhibits osteoporosis, fights some mental disorders, and in some cases has been found to be an anti-cancer agent. Lexaria Bioscience is simply enhancing these benefits of hemp oil by enhancing the amount of hemp oil a human body can absorb when ingested.

    Simply put, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. The key to the science is the fact that Lexaria Bioscience is able to combine cannabinoids with lipids — or fatty acids — at the molecular level. It matters, because the human endocannabinoid system is it

Top Gold Stocks To Own For 2018: PetroChina Company Limited(PTR)

Advisors’ Opinion:

  • [By Money Morning News Team]

    PetroChina Co. Ltd. (NYSE ADR: PTR) is China’s largest oil company with a market cap of $216.52 billion. PTR is partially owned by the Chinese government.

Top Gold Stocks To Own For 2018: Atkore International Group Inc. (ATKR)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Flexing the barbell strategy to balance Safe Havens with more cyclical exposures. In our view, industrials investors should be positioning their portfolio with a barbell strategy, with half of the exposure in Safe Havens like General Electric, Xylem (XYL), Danaher, Honeywell International, Roper Technologies (ROP), and AMETEK (AME), and the other half selectively in the cyclical names that are better positioned today, such as Pentair, HD Supply Holdings (HDS),Actuant (ATU), Atkore International Group (ATKR), Ingersoll-Rand, and Eaton (ETN). We still believe risk-reward is mostly balanced and that the macro will remain choppy into 2017, supporting a positioning in the defensive names. But if investor sentiment improves on not-worse news and earnings results, the more cyclical names could fare better.

  • [By Spencer Israel]

    3. Atkor International Group Inc (NYSE: ATKR) – Five of the six analyst ratings on the manufacturing holding company have been bullish. With the stock showing very strong technical support at $16, and currently trading at $16.68, Stockal's confidence meter is at 90%. 

Top Gold Stocks To Own For 2018: Atlantia S.p.A. (ATASF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Atlantia (ATASF) (AT.IM), Eiffage (OTCPK:EFGSY) (FGR.FP), Ferrovial (OTC:FRRVF) (FER.SM), Albertis (OTC:ABFOF) (ABE.SM) and Vinci (OTCPK:VCISF) (DG.FP)

Top Gold Stocks To Own For 2018: Eagle Bulk Shipping Inc.(EGLE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Eagle Bulk Shipping Inc (NASDAQ: EGLE) were down 49 percent to $0.381. Eagle Bulk Shipping announced after Wednesday’s close it has reached an agreement with its lenders and holders of its equity to raise $105 million.